Controversial New Alzheimer’s Drug Approved Despite Reservations
Follow via Flickr Link: https://www.flickr.com/photos/alzmglc/15311519476/in/photolist-pk2xi7-p5zz1T-pn36eW-pk2z4G-pn4Zzt-p5yHLJ-p5yCyQ-p5yy7H-p5yKrY-p5zBtP-pn2YxE-pn4BVM-p5ztkA-pmMonT-p5ziQo-bxQfpz-pmMxTM-p5zXeR-p5zbib-p5zQFk-pn3m45-pk2Tsf-p5zB8E-pn4N6g-4eGjGS-CFX1-pk2JQf-WfWjgu-pk2Lc3-3hQn2G-4kkzZx-6DojR2-51m44-7rJbFK-9YAmBr-fkWSC9-44Aksc-nSqng6-GAH7BD-j1M1Sk-gv1YhP-6Doi7x-3xK9k-6DoitF-dwaKm8-fkWSGw-6DoiYK-6DssxN-MhcFWN-o17RFw
The U.S. Food and Drug Administration has approved the first new drug for Alzheimer’s disease in 20 years, but some doctors, including one at UAB, warned patients’ families not to expect much from the drug any time soon.
The drug, aducanumab, is expected to help slow the progression of the disease, but not to improve current memory impairments, according to a release from the University of Alabama at Birmingham. The university’s Division of Memory Disorders and the Alzheimer’s Disease Center have been involved in clinical trials of aducanumab for the past five years.
“The approval of the first disease-modifying therapy is a milestone for our field and a result of years of intense research. However, it must be understood that [aducanumab] is not expected to restore memory or reverse the symptoms of Alzheimer’s disease,” said Dr. David Geldmacher, professor of neurology at UAB and clinical core director of the center. “Instead, it is expected to slow the worsening of the disease. [Aducanumab] is likely the beginning of a new era in treating AD, but not the end of the story.”
Geldmacher said it would be some time before the drug is widely available, not all patients will be eligible to receive it, and many patients, especially with advanced disease, are not likely to see improvement from it.
The FDA approved the drug despite opposition from an independent advisory committee and some Alzheimer’s experts who said there was not enough evidence the drug helps patients, according to several news reports, including from the Associated Press.
The FDA did require the drugmaker, Biogen, to conduct another study to determine whether it benefits patients, and it could pull the drug from the market if its effectiveness is not proven.
Editor’s Note: UAB holds WBHM’s broadcast license, but our news and business departments operate independently.
Crew of fatal US military crash included Alabama father recently deployed
The six U.S. service members who died in the crash of a U.S. military refueling aircraft included an Alabama father who had just been promoted and deployed. The U.S. government released the identities of the deceased service members Saturday.
Alabama poised to drastically overhaul utility regulation. Will it lower electric bills?
The Alabama Senate unanimously voted to expand the public service commission, and create a Secretary of Energy to address rising electricity prices. A bill in the House would go even further, requiring rate case hearings and limiting utility profits.
Musher from Alabama is going for back-to-back Iditarod wins
Riches and paid appearances haven’t followed Jessie Holmes since he won the world’s most famous sled dog race, the Iditarod, last year. He doesn't mind.
Bill would move Alabama to closed primaries
Right now, any Alabama voter can participate in a primary election. Lawmakers in Montgomery took up a bill this week that would change that system.
Auburn football player uses NIL funds to open a community hub in Birmingham
Jourdin Crawford, a freshman defensive lineman at Auburn, used earnings from a Name, Image, and Likeness deal to give back to his hometown.
Ivey commutes death sentence of inmate whose accomplice fired fatal shot
Charles “Sonny” Burton was sentenced to death for the killing of Doug Battle during a 1991 robbery. However, another man shot Battle when Burton had left the building.
